Economic burden of spinal muscular atrophy: an analysis of claims data

Background: Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease. Objective: Characterize direct costs associated with SMA management. Data source: Truven Health Analytics MarketScan claims data (2012–2016). Patients: Eligible patients had ≥2 SMA-related medical claims ≥30 days apar...

Full description

Bibliographic Details
Main Authors: Lisa Belter, Rosángel Cruz, Sierra Kulas, Emily McGinnis, Omar Dabbous, Jill Jarecki
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Journal of Market Access & Health Policy
Subjects:
Online Access:http://dx.doi.org/10.1080/20016689.2020.1843277